I-287 is an Orally Active PAR2 Inhibitor for Inflammation Research
Effect of I-287 on intracellular signaling pathways induced by the two human PAR2 agonists, Trypsin, and SLIGKV-NH2.
Effect of I-287 on intracellular signaling pathways induced by the two human PAR2 agonists, Trypsin, and SLIGKV-NH2.
Kinases typically integrate signaling events down-stream of multiple cytokine receptors. Hence, kinase inhibitors distinguish themselves from cytokine-targeted biologicals by their capacity to modulate multiple signaling pathways simultaneously. IL-1 receptor (IL-1R)–associated…